The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing chikungunya disease in adults only, although, it is in clinical ...

The French biotech is the first company to bring a chikungunya vaccine to market, getting FDA approval for its Ixchiq (VLA1553) shot in November 2023 and in Europe and Canada in June, for adults ...

The agency approved the company's chikungunya vaccine, Ixchiq, for use in people 18 years of age and older. Late-stage trial data show the vaccine "induces a rapid and strong immune response ...

PALFINGER MARINE secures a major contract with the Finnish Meyer Turku shipyard to provide lifesaving appliances (LSA) for Royal Caribbean International’s fourth Icon Class ship, set to debut in 2027.